drugset / Trial / NCT01055379
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
Phase 4
Completed
121 enrolled
Lundbeck Italia S.p.A.
Teva Branded Pharmaceutical Products R&D, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rasagiline | Small molecule | 1 mg | Oral |